Novel Antitumoral Use Of Cabazitaxel

Patent No. EP2493466 (titled "Novel Antitumoral Use Of Cabazitaxel") was filed by Aventis Pharma on Oct 27, 2010. The application was issued on Mar 10, 2021.

Patent Summary

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_CFI_503/2024Sep 2, 2024Zentiva, Zentiva FranceCounter Claim For Revocation
UPC_CFI_496/2024Sep 2, 2024Stada Arzneimittel, Stada NordicCounter Claim For Revocation
UPC_CFI_463/2024Aug 30, 2024Accord Healthcare, Accord Healthcare ABCounter Claim For Revocation
UPC_CFI_374/2024Aug 29, 2024Betapharm Arzneimittel, DR ReddysCounter Claim For Revocation
APP_34720/2024Jun 26, 2024Medac Gesellschaft FUR Klinische SpezialpraparateGeneric
UPC_CFI_148/2024May 13, 2024Sanofi, Sanofi ABInfringement
UPC_CFI_147/2024May 13, 2024Sanofi, Sanofi ABInfringement
UPC_CFI_146/2024May 13, 2024Sanofi, Sanofi ABInfringement
UPC_CFI_145/2024May 13, 2024Sanofi, Sanofi ABInfringement

Patent Family

Patent Family

Patent Oppositions (15)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2493466

AVENTIS PHARMA
Application Number
EP10782039A
Filing Date
Oct 27, 2010
Status
Opposition Rejected
Sep 19, 2025
Publication Date
Mar 10, 2021